Sophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, discusses a trial analyzing the benefit for radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.

The primary aim of this study was to show a 10% reduction in prostate cancer mortality. The final analysis (median follow-up of 11 years) showed about an 11% reduction in prostate cancer-specific mortality.

Fosså believes that the benefit actually was even greater, as elderly men die of other causes which cannot be affected by treatment. Fosså says there are plans to analyze how many patients died of cardiovascular disease. This is an important question to answer as castration treatment can increase the risk of cardiovascular disease.

View more from the 2014 GU Cancers Symposium

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Prostate Cancer

JAN-22-OSD1189 - /clinical/prostate-cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Genitourinary Cancers Symposium (ASCO GU)

Sophie D. FossÃ¥, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, discusses a trial analyzing the benefit for radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.

Dr. FossÃ¥ on Radiotherapy/ Antiandrogen Therapy